TEQCool AB today announced a strategic repositioning of its patented non-invasive, intranasal brain cooling system technology to address the vast global market for brain metabolism reduction, expanding beyond the therapeutic hypothermia market.
Addressing a Critical, Under-Served Need
While dedicated standalone markets for targeted brain temperature reduction do not yet exist, the underlying demand spans multiple established segments, TEQCool is now targeting a spectrum of life-threatening neurological conditions—opening access to markets projected to exceed $84 billion by 2030:
- Traumatic Brain Injury (TBI): $13.7 billion
- Subarachnoid Hemorrhage (SAH): $4.2 billion
- Status Epilepticus (SE): segment of the $2.1 billion
- Stroke (Ischemic & Hemorrhagic): $61.7 billion by
- Neonatal Hypoxic-Ischemic Encephalopathy (HIE): $1.9 billion
Each of these multi-billion-dollar markets underscores the urgent need for superior neuroprotection—and positions TEQCool to capture significant share by integrating seamlessly into existing treatment protocols.
Fueling Innovation with Clinical Collaboration
“Built on decades of Lund University research and refined through pre-clinical and early clinical studies, TEQCool’s technology has garnered enthusiastic endorsement from the neuro-critical community. Our interviews with leading neurosurgeons, intensivists and neurocritical-care specialists, continues to point to one thing: there is no tool like TEQCool, they recognize that precisely lowering brain temperature and oxygen demand could be the game-changer in preventing secondary injury—yet until now, no technology has been capable of delivering rapid, targeted cooling without risking whole-body hypothermia or invasive procedures. It’s obvious to us that if they have a rapid, targeted, non-invasive brain cooling option like the TEQCool’s technology, they will use cooling more in reducing brain metabolism and preventing secondary injury.” says the Anders Sjögren, CEO.
A Proven, Patented Platform with Unmatched Precision
TEQCool’s system employs patented balloon catheters inserted into the nasal cavity and nasopharynx to harness the body’s natural heat-exchange pathways. With the potential to achieve targeted brain cooling of approximately 2 °C within one hour—without surgery or deep sedation, this unique approach has the potential to minimize systemic complications and keep the patient fully accessible to clinicians throughout treatment.
To Our Highly Esteemed Investors
“The journey ahead of us is definitely exciting and promising,” says Vivien Ibironke Ibiyemi, COO of TEQCool. TEQCool invites current and prospective shareholders to join in this pivotal expansion. With regulatory pathways advancing and initial clinical data demonstrating both safety and efficacy, we are poised to accelerate product development and commercial rollout across major global markets.
